Why Is Autonomix Medical (NASDAQ:AMIX) Climbing 10.00% Pre-Market on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Is Autonomix Medical (NASDAQ:AMIX) Climbing 10.00% Pre-Market on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Autonomix Medical (NASDAQ:AMIX) is quoted at USD 1.87 before the open on Tuesday, November 10, 2026, up 10.00% from a calculated prior close of USD 1.70, which lines up with the November 9 close.
Monday's session already added USD 0.18, or 11.84%, on 342,889 shares traded between USD 1.53 and USD 1.77.
Market capitalisation stands at USD 3.33 million on 1.96 million shares, down 32.9%, against a 52-week span of USD 1.46 to USD 32.55.
The company posted a loss of USD 16.11 million, or USD 36.37 per share, while its latest quarterly filing showed cash of USD 9.9 million against a funding requirement of USD 30 million to USD 36 million.

Drivers Behind Autonomix Medical's Pre-Market Gain (+10.00%)

The pre-market price of USD 1.87 sits 10.00% above the USD 1.70 close on November 9, 2026, a rise of USD 0.17 a share. Shares had already climbed 11.84% on Monday, so this looks more like a second leg of a rebound than a new surge. Nothing dated November 9 or 10, 2026 turned up as a company release or filing, which leaves no catalyst to name. The newest items located date from September 30, 2026, when the company said FDA pre-submission feedback backed a 510(k) route for its standalone device, and from early October 2026, when it announced a Canadian patent. Both are weeks old and cannot be confirmed as the trigger.

Why Small Device Makers Often Move on Thin Trading

As general context, pre-revenue device companies frequently trade on regulatory updates, Patent announcements, financing news and technical rebounds. Autonomix is building a catheter-based platform for nerve sensing and ablation, and a 510(k) route can shorten the path to US clearance relative to a full premarket approval. Shareholders also track the cash runway: the latest quarter, ended December 31, 2025, recorded a net loss of USD 3.3 million and cash of USD 9.9 million, and management said cash would last into the third quarter of calendar 2026. With 1.96 million shares in issue, a 10% move can follow a few thousand shares of buying. Two analysts rate the shares Buy with an average target of USD 40.80, a level far above the Market Price that trading has not tested.

Valuation, Liquidity and Risks for Autonomix Medical (NASDAQ:AMIX)

At USD 1.87 the calculated Market Value is about USD 3.7 million, below the USD 9.9 million of cash reported at December 31, 2025, although the company has burned cash since then and may have raised funds that this review could not verify. The shares trade 94% below their 52-week high of USD 32.55, a calculated figure, and only 28% above the low of USD 1.46. Autonomix needs an estimated USD 30 million to USD 36 million more to reach commercial sales of its first indication, so dilution through share offerings or reverse splits is the main hazard. Spreads can be wide before 9:30 a.m. ET, and a Reversal is still possible. Pre-market sessions run from 4:00 a.m. to 9:30 a.m. ET with far fewer participants than the regular session. The company has no revenue, so there are no sales figures to anchor a valuation. None of this suggests the move will last.

Where Things Stand

Autonomix Medical (NASDAQ:AMIX) is up 10.00% pre-market, with no catalyst identified in published reporting as of November 10, 2026. The shares follow an 11.84% gain on November 9, so momentum in a 1.96 million share float is the most likely mechanism, offered as general context. Funding needs and dilution risk remain the main constraints.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.